CYP2A6 IS A PRINCIPAL ENZYME INVOLVED IN HYDROXYLATION OF 1,7-DIMETHYLXANTHINE, A MAIN CAFFEINE METABOLITE, IN HUMANS
- 1 September 2005
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 33 (9) , 1361-1366
- https://doi.org/10.1124/dmd.105.004796
Abstract
In a caffeine test previously performed with healthy Japanese volunteers, we found that the CYP1A2 index defined as urinary {5-acetylamino-6-amine-3-methyluracil (AAMU) + 1-methylxanthine (1X) + 1-methyluric acid (1U)}/1,7-dimethyluric acid (17U) was affected by the whole deleted allele of CYP2A6 (CYP2A6*4). Since the high value of the CYP1A2 index could be caused by a low urinary concentration of 17U, we postulated that CYP2A6 was responsible for the 1,7-dimethylxanthine (17X) metabolism to generate 17U (17X 8-hydroxylation). Thus, the role of CYP2A6 in the 17X 8-hydroxylation was fully examined in the present study. Among 10 isoforms of human cytochrome P450 (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, or CYP3A5) expressed in Escherichia coli cells, CYP2A6 and CYP1A2 showed high catalytic activities for the 17X 8-hydroxylation. The 17X 8-hydroxylase activities significantly associated with coumarin 7-hydroxylase activities (r = 0.67, p < 0.01) in liver microsomes from 17 individuals, but not with ethoxyresorufin O-deethylase activities. Tranylcypromine, an inhibitor of CYP2A6, reduced the 17X 8-hydroxylase activities of human liver microsomes. The 17X 8-hydroxylase activities of CYP2A6.7, CYP2A6.10, and CYP2A6.11 expressed in E. coli cells were 12, 13, and 22% of that of CYP2A6.1, respectively. The 17X 8-hydroxylase activities were found to be low in liver microsomes from individuals possessing the deletion or mutations in the CYP2A6 gene. Based on these data, we conclude that CYP2A6 is a main 17X 8-hydroxylase and that the catalytic activities for the 17X 8-hydroxylation are reduced by the genetic polymorphisms of the CYP2A6 gene.Keywords
This publication has 33 references indexed in Scilit:
- Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokersCarcinogenesis: Integrative Cancer Research, 2004
- Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9)Pharmacogenetics, 2003
- Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolismBritish Journal of Clinical Pharmacology, 2002
- CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stabilityBiochemical and Biophysical Research Communications, 2002
- An in Vivo Pilot Study Characterizing the New CYP2A6*7, *8, and *10 AllelesBiochemical and Biophysical Research Communications, 2002
- A Novel Single Nucleotide Polymorphism Altering Stability and Activity of CYP2A6Biochemical and Biophysical Research Communications, 2001
- A Single Nucleotide Polymorphism of CYP2B6 Found in Japanese Enhances Catalytic Activity by AutoactivationBiochemical and Biophysical Research Communications, 2001
- Inhibition of Coumarin 7-Hydroxylase Activity in Human Liver MicrosomesArchives of Biochemistry and Biophysics, 1997
- Interindividual variability of coumarin 7-hydroxylation in healthy volunteersPharmacogenetics, 1992
- Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1Pharmacogenetics, 1992